With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
Executive Summary
Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting
You may also be interested in...
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
J&J's abiraterone is cleared for use two months ahead of schedule. Pricing of $5,000 a month is much lower than Dendreon's Provenge, approved for earlier stage disease.